

AWARD NUMBER: W81XWH-19-1-0717

TITLE: **A Novel Imaging Agent for Detecting and Monitoring Lupus Nephritis**

PRINCIPAL INVESTIGATOR: **Joshua Thurman**

CONTRACTING ORGANIZATION: **University of Colorado Denver**  
Aurora, CO

REPORT DATE: **October 2021**

TYPE OF REPORT: **Annual Report**

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

<b>1. REPORT DATE</b> October 2021		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 01Sep2020-31Aug2021	
<b>4. TITLE AND SUBTITLE</b>  A Novel Imaging Agent for Detecting and Monitoring Lupus Nephritis				<b>5a. CONTRACT NUMBER</b> W81XWH-19-1-0717	
				<b>5b. GRANT NUMBER</b> LR180050	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Joshua Thurman				<b>5d. PROJECT NUMBER</b> 25A8405	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  University of Colorado Denver Mail Stop F428 Anschutz Medical Campus, Building 500 13001 East 17th Place, Room W1126 Aurora, Colorado 80045 USA				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> This is a project to develop methods for detecting and monitoring inflammation in patients with systemic lupus erythematosus (SLE) in order to non-invasively detect tissue inflammation. This method will allow clinicians to: 1) more accurately identify which patients with SLE need to be treated with immunosuppressive drugs, and 2) determine whether immunosuppressive treatment of these patients is effective. These imaging methods will provide the same information that can currently be obtained only by an invasive tissue biopsy. Because these imaging methods expose patients to very low levels of radiation, they can be repeated as needed to assess changes over time. These methods will directly improve the care of patients with SLE because an accurate method of monitoring tissue inflammation will reduce permanent organ damage by under-treatment of the disease while also reducing side effects caused by unnecessary treatment.					
<b>15. SUBJECT TERMS</b> None listed.					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>19b. TELEPHONE NUMBER</b> (include area code)
Unclassified	Unclassified	Unclassified	Unclassified	7	USAMRMC

## TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	5
5. Changes/Problems	6
6. Products	6
7. Participants & Other Collaborating Organizations	6
8. Special Reporting Requirements	7
9. Appendices	7

## **1. Introduction**

This is an annual report for the project entitled: "A Novel Imaging Agent for Detecting and Monitoring Lupus Nephritis." The PI is Joshua Thurman, MD, and it covers the second year of this grant (7/01/20 – 6/30/21).

This is a project to develop methods for detecting and monitoring inflammation in patients with systemic lupus erythematosus (SLE). SLE is an autoimmune disease that can affect multiple different organs, including the kidneys, heart, intestine, and central nervous system. SLE is a lifelong disease marked by flares and remissions. The treatment of SLE almost always includes medicines that suppress the immune response. Immunosuppressive drugs, such as cyclophosphamide and mycophenolate mofetil, reduce tissue inflammation and injury, and the mortality for patients with SLE has improved in recent decades. Aggressive and prolonged immunosuppression reduces - but does not eliminate - the risk of future flares. Consequently, even patients who have remained in remission for prolonged periods need to continually be monitored for evidence of a disease flare, and these flares usually require patients to re-start treatment. However, the immunosuppressive drugs currently available also have many side effects. Most importantly, these drugs increase patients' risk of infections. Treatment, therefore, should be minimized in patients who are in remission and do not have active tissue inflammation.

The imaging methods that we are developing in this project offer the possibility of non-invasively detecting tissue inflammation in patients with lupus. It will allow clinicians to: 1) more accurately identify which patients with SLE need to be treated with immunosuppressive drugs, and 2) determine whether immunosuppressive treatment of these patients is effective. These imaging methods will provide the same information that can currently be obtained only by an invasive tissue biopsy. Furthermore, biopsies sample only a small portion of tissue, and these imaging methods will report on inflammation throughout the whole organ and throughout the entire body. Because these imaging methods expose patients to very low levels of radiation, they can be repeated as needed to assess changes over time. These methods will directly improve the care of patients with SLE because an accurate method of monitoring tissue inflammation will reduce permanent organ damage by under-treatment of the disease while also reducing side effects caused by unnecessary treatment.

## **2. Keywords**

Kidney, complement, diagnostic, positron emission tomography

## **3. Accomplishments**

### **What were the major goals of the project?**

The major goals of this project as outlined in the Statement of Work (SOW) are:

1. Production of recombinant proteins and monoclonal antibodies.
2. Confirm in vivo targeting and specificity of anti-C3d probes
3. Test anti-C3d probes in a model of lupus-like glomerulonephritis.
4. Test anti-C3d probes in mice with lupus-like glomerulonephritis treated with conventional immunosuppression (cyclophosphamide).

### **What was accomplished to date under these goals?**

**Goal 1.** We have produced a sufficient quantity of recombinant C3d and monoclonal antibody for the proposed studies.

**Goal 2.** We have produced sufficient Fab and minibody (Fab2) for the experiments. We successfully created the near-infrared bioluminescence resonance energy transfer (BRET) construct to label the imaging probes for optical imaging.

**Goal 3.** We have obtained IACUC approval for the experiments, and we have expanded our colony of mice for the experiments (factor H knockout mice and factor H/factor B double knockout mice). The whole IgG probe has been tested in the mouse model of glomerulonephritis, and we confirmed that the labeled probe binds to tissue sites of C3d. Specificity has been confirmed using control mice and control probe.

We also tested radiolabeled forms of the probes (whole IgG, Fab, and Fab2) in a mouse model of lupus nephritis. All three probes successfully detected tissue C3d deposits. The whole IgG gave the strongest signal.

### **What opportunities for training and professional development has the project provided?**

Nothing to report.

### **How were the results disseminated to communities of interest?**

Nothing to report.

### **What do you plan to do during the next reporting period to accomplish the goals?**

During the next funding period we expect to:

- Continue the proposed animal imaging experiments to determine conditions for optimal detection of tissue C3d
- Test the radiolabeled probes in mice treated with cyclophosphamide to determine whether the imaging signal accurately represents the response to treatment.

## **4. Impact**

### **What was the impact on the development of the principal discipline(s) of the project?**

Nothing to report at this phase of the project.

### **What was the impact on other disciplines?**

Nothing to report at this phase of the project.

### **What was the impact on technology transfer?**

Nothing to report at this phase of the project.

### **What was the impact on society beyond science and technology?**

Nothing to report at this phase of the project.

## **5. Changes/Problems**

### **Changes in approach and reasons for change**

Nothing to report.

### **Actual or anticipated problems or delays and actions or plans to resolve them**

The shutdown of our laboratories due to the COVID-19 pandemic last year delayed the accomplishment of some of the experiments. Nevertheless, the experiments are proceeding, and we anticipate completing the proposed experiments within the planned timeframe of the project.

### **Changes that had a significant impact on expenditures**

Nothing to report.

### **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to report.

### **Significant changes in use or care of human subjects**

Nothing to report.

### **Significant changes in use or care of vertebrate animals.**

Nothing to report.

### **Significant changes in use of biohazards and/or select agents**

Nothing to report.

## **6. Products**

### **Publications, conference papers, and presentations**

This data was presented at the Lupus 21<sup>st</sup> Century Meeting (Sept 22-25, 2021). Our plan is for all experimental results and analyses to be published, although there are not yet any publications to report.

### **Website(s) or other Internet site(s)**

Nothing to report.

### **Technologies or techniques**

Nothing to report.

### **Inventions, patent applications, and/or licenses**

Nothing to report.

### **Other Products**

Nothing to report.

## 7. Participants & Other Collaborating Organizations

**What individuals have worked on the project?**

Name:	Catherine Foss, PhD,
Project Role:	Co-investigator
Research Identifier:	
Nearest person month worked:	2.4 calendar months
Contribution to project:	Dr. Foss is an expert in radiochemistry and nuclear medicine.
Funding Support:	This project.

**Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

No change.

**What other organizations were involved as partners?**

There have been no changes from the original proposal regarding the organizations involved in the project:

University of Colorado Denver  
1775 Aurora Court  
Aurora, CO USA

Johns Hopkins University  
733 N. Broadway, Suite 117  
Baltimore, MD USA

## 8. Special Reporting Requirements

Not applicable.

## 9. Appendices

Not applicable.